Cerebellar Receptor Loss Coexisted With Preserved Cyclase Inhibition in Cannabinoid-Tolerant Mice
A CP55,940 tolerance study reported substantial behavioral adaptation and reduced cerebellar receptor number, yet little change in the compound's inhibition of adenylyl cyclase. Receptor loss did not translate directly into a matching reduction at that downstream endpoint.
Behavioral tolerance differed across measures
Repeated treatment reduced sensitivity to movement suppression, hypothermia and immobility by different amounts. Those dose-response shifts show that tolerance magnitude depended on the outcome. They should not be condensed into one universal cannabinoid tolerance factor.
The tissue findings were not all aligned
The study reported lower cerebellar receptor number without a corresponding affinity change, alongside increased receptor mRNA. Nevertheless, inhibition of adenylyl cyclase differed little between control and treated groups. Binding availability, gene expression and downstream functional response therefore gave different information.
Spare receptors were one possible explanation
The authors proposed that enough receptors might remain to sustain the maximal downstream response. They also questioned whether downregulation accounts for tolerance to every effect. The spare-receptor explanation was a possibility, not a directly established conclusion eliminating other mechanisms.
The study supports caution when predicting function from receptor abundance alone. Its evidence concerns a synthetic agonist, a mouse regimen and a cerebellar assay. It does not show that receptor loss is harmless or that preserved enzyme inhibition guarantees normal movement, cognition or performance in cannabis users.
Related: interpreting cannabis tolerance claims.
Research cited
Fan F; Tao Q; Abood M; Martin BR. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain research (1996). doi:10.1016/0006-8993(95)01113-7. Findings discussed from the study abstract.
